A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

HPV Infections Clinical Trial

Official title:

A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03900572
• Other study ID #: 312-HPV-2001
• Status: Completed
• Phase: Phase 1
• Start date: March 9, 2019
• Est. completion date: April 30, 2020

Study information

• Verified date: April 2023
• Source: Shanghai Zerun Biotechnology Co.,Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9 to 45 years old healthy Chinese females.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: April 30, 2020
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 9 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy females, 9 to 45 years old (inclusive).
• 9 to 17 years old participants: able to prove their identities and provide their legal guardians' identity information.
• Legal guardians of the 9 to 17 years old participants: able to understand (not illiterate) and agree to co-sign the informed consent forms with participants
• 18 to 45 years old participants: able to prove their legal identities.
• 18 to 45 years old participants: able to understand (not illiterate) the study and agree to sign the informed consent form.
• Child bearing age participants: agree not to become pregnant by using proper contraception means in the 7-month study period.

Exclusion Criteria:

• History of cervical cancer or genital warts.
• History HPV vaccination or history of participation in HPV vaccine trial.
• History of severe allergy which needs medical intervention such as swelling of the mouth and throat, difficulty breathing, hypotension or shock.
• Skin abnormality at injection site including inflammation, sclerosis, redness, swelling, and extensive scars.
• History of allergy to vaccine or vaccine components including aluminum phosphate, histidine and Polysorbate 80, and severe adverse reactions in past vaccination.
• Medical history of epilepsy, convulsions, seizures , or family history of mental illness.
• Medical conditions including immunocompromised or diagnosed as congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases and received immunosuppressants in 6 months prior to first vaccination.
• History of asthma, thyroidectomy, angioneurotic edema, diabetes, and malignancy.
• Asplenia, functional asplenia, or any circumstances as a result of asplenia or splenectomy
• Diagnosis as coagulation abnormalities such as clotting factor deficiency, platelet abnormalities or having significant bruising, or coagulation disorder
• Being diagnosed with acute illnesses or acute onset of chronic illness during the last 3 days.
• Treatment with immunoglobulins or other blood-derived products within 3 months prior to Day 0 vaccination.
• Having received subunit or inactivated vaccine within 14 days prior to Day 0 vaccination or received attenuated vaccine within 28 days prior to Day 0 vaccination.
• Fever before vaccine administration with axillary temperature higher than 37.0°C.
• Currently breastfeeding, and being pregnant including pregnancy test positive.
• History of hypertension: Participants of 13 to 45 years of age have their respective systolic blood pressure greater than 150 mmHg and/or diastolic blood pressure greater than 100 mmHg; or participants of 9 to 12 years of age demonstrate their respective systolic blood pressure higher than 120 mmHg and/or diastolic blood pressure higher than 80 mmHg.
• Exhibits of abnormal lab test parameters.
• Any other factors which might affect any individual to be enrolled in the study according to the investigator's judgment.

Related Conditions & MeSH terms

• HPV Infections
• Papillomavirus Infections

Intervention

Biological:
• HPV Vaccine
Intramuscular injection, 3 doses

Drug:
• Placebo
Intramuscular injection, 3 doses

Locations

Country	Name	City	State
China	Sichuan Provincial Center for Disease Prevention and Control	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zerun Biotechnology Co.,Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects Reporting Solicited Local Symptoms	Solicited local symptoms assessed including pain, redness, swelling, induration and itching.	During a 8-day period (Day 0-7) following each vaccination
Primary	Percentage of Subjects Reporting Solicited General Symptoms	Solicited general symptoms assessed including fever, headache, fatigue, nausea, diarrhea, vomiting, myalgia, allergic reaction	During a 8-day period (Day 0-7) following each vaccination
Primary	Percentage of Subjects Reporting Unsolicited Adverse Events (AEs)	An unsolicited adverse event is defined as any adverse event (AE) reported in addition to those solicited during the clinical study.	Within 31 days (Day 0-30) after any vaccination
Primary	Percentage of Subjects Reporting Serious Adverse Events (SAE)	Serious adverse events are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.	Throughout the study period (up to Month 12)
Secondary	Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58	Seroconversion is defined as a participant who was anti-HPV seronegative at Day 0 (before vaccination) and became seropositive 30days after the third dose (Month 7).	30 days after the third dose (Month 7)
Secondary	Geometric Mean Titers (GMT) of HPV serotype-specific antibody	HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 specific antibodies GMT	30 days after the third dose (Month 7)